(NASDAQ: SCYX) Scynexis's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 14.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.
Scynexis's earnings in 2026 is -$24,517,000.On average, 5 Wall Street analysts forecast SCYX's earnings for 2026 to be -$32,952,804, with the lowest SCYX earnings forecast at -$41,262,503, and the highest SCYX earnings forecast at -$16,682,953. On average, 5 Wall Street analysts forecast SCYX's earnings for 2027 to be -$19,717,661, with the lowest SCYX earnings forecast at -$26,470,285, and the highest SCYX earnings forecast at -$8,341,476.
In 2028, SCYX is forecast to generate -$15,936,192 in earnings, with the lowest earnings forecast at -$21,799,058 and the highest earnings forecast at -$8,341,476.